CLIGF:OTC-Clinigen Group plc (USD)

COMMON STOCK | | OTC

Last Closing Price

USD 7.70

Change

0.00 (0.00)%

Market Cap

USD 1.75B

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Clinigen Group plc operates as a specialty pharmaceutical and services company. The company operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines in the Africa and Asia Pacific region. The Unlicensed Medicines segment is involved in sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Clinical Trial Segment supplies and manages comparator medicines and services to clinical trials and investigator initiated trials. It offers Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Foscavir, an anti-virals which work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company has a strategic alliance with Cumberland Pharmaceuticals Inc. Clinigen Group plc was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-06 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BTHI Big Time Holdings, Inc

N/A

USD151.65B N/A N/A
DFIFF Diamond Fields Resources Inc

N/A

USD108.83B 39.43 N/A
YACAF Yancoal Australia Ltd

N/A

USD57.90B 0.20 N/A
SEMHF Siemens Healthineers AG

N/A

USD53.41B 36.83 N/A
HENOF Henkel AG & Co. KGaA

N/A

USD45.41B 15.79 12.92
WXIBF WuXi Biologics (Cayman) Inc

N/A

USD45.16B 256.25 38.43
HDALF Haidilao International Holding..

N/A

USD42.13B 79.20 11.85
MQBKY Macquarie Group Limited

N/A

USD40.81B 24.50 8.77
SARTF Sartorius Aktiengesellschaft

N/A

USD37.87B 114.64 N/A
SUVPF Sartorius Aktiengesellschaft

N/A

USD34.52B 264.59 N/A

ETFs Containing CLIGF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification ()
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -14.44% N/A N/A 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.44% N/A N/A 19% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -7.87% N/A N/A 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.87% N/A N/A 20% F
Risk Return Profile  
Volatility (Standard Deviation) 13.56% N/A N/A 86% B
Risk Adjusted Return -58.05% N/A N/A 13% F
Market Capitalization 1.75B N/A N/A 72% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
()
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 50.10 N/A N/A 14% F
Price/Book Ratio 3.29 N/A N/A 34% F
Price / Cash Flow Ratio 36.81 N/A N/A 5% F
EV/EBITDA 206.12 N/A N/A 3% F
Management Effectiveness  
Return on Equity 6.52% N/A N/A 62% D-
Return on Invested Capital 8.62% N/A N/A 70% C-
Return on Assets 4.19% N/A N/A 81% B-
Debt to Equity Ratio 49.44% N/A N/A 35% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.56 N/A N/A 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.